Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

BACKGROUND: There is ambiguity whether frail patients with atrial fibrillation managed with
vitamin K antagonists (VKAs) should be switched to a non–vitamin K oral anticoagulant …

Patients aged≥ 65 years not only account for the majority of patients with atrial fibrillation
(AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity …

Importance There are no data on patient-centered outcomes and health care costs by frailty
in patients with atrial fibrillation (AF) taking oral anticoagulants (OACs). Objective To …

BACKGROUND: The very elderly (≥ 80 years) are at high risk of nonvalvular atrial
fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness …

Background Data on non-vitamin K antagonist oral anticoagulant (NOAC) use in patients
with atrial fibrillation (AF) and a history of falls are limited. Therefore, we investigated the …

Настоящий обзор рассматривает позиции апиксабана среди других прямых оральных
антикоагулянтов у больных фибрилляцией предсердий (ФП) и венозными тромбозами …

Gebrechliche alte Menschen gelten als besonders gefährdet, eine unerwünschte
Arzneimittelwirkung zu erleiden. Empirische Studien belegen die erhöhte Rate …

Background: The very elderly (≥ 80 years) are at high risk of nonvalvular atrial fibrillation
(NVAF) and thromboembolism, as older age represents the most prominent risk factor for …

Background: Data on non-vitamin K antagonist oral anticoagulant (NOAC) use in patients
with atrial fibrillation (AF) and a history of falls are limited. Therefore, we investigated the …